Catalyst Wire Dossier Catalyst Wire Dossier

Autologous T cells expressing neoantigen-reactive T-cell receptors

· National Cancer Institute
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous T cells expressing neoantigen-reactive T-cell receptors, covering 2026-04-24 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer [Phase 2]

See pricing